LIPO Stock Price, Lipella Pharmaceuticals . Quote, Chart

Market Summary

USD0.760.00

Delayed

0.00%

LIPO Stock Price

View Fullscreen

LIPO RSI Chart

LIPO Valuation

Market Cap

5.8M

Price/Earnings (Trailing)

-1.22

Price/Sales (Trailing)

12.11

EV/EBITDA

-0.78

Price/Free Cashflow

-1.66

LIPO Price/Sales (Trailing)

LIPO Profitability

EBT Margin

-993.39%

Return on Equity

-185.18%

Return on Assets

-151.19%

Free Cashflow Yield

-60.12%

LIPO Fundamentals

LIPO Revenue

Revenue (TTM)

477.4K

Rev. Growth (Yr)

23.58%

Rev. Growth (Qtr)

20.72%

LIPO Earnings

Earnings (TTM)

-4.7M

Earnings Growth (Yr)

-11.61%

Earnings Growth (Qtr)

-73.01%

Breaking Down LIPO Revenue

Last 7 days

4.1%

Last 30 days

1.3%

Last 90 days

-24%

How does LIPO drawdown profile look like?

LIPO Financial Health

Current Ratio

5.46

LIPO Investor Care

Shares Dilution (1Y)

32.41%

Diluted EPS (TTM)

-0.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	477.4K	0	0	0
2023	269.1K	375.7K	479.8K	449.6K
2022	240.5K	221.8K	203.0K	184.2K
2021	0	0	0	259.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lipella Pharmaceuticals Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 19, 2024	kaufman jonathan h	bought	21,802	0.8721	25,000	see remarks below.
Mar 18, 2024	kaufman jonathan h	bought	23,649	0.7883	30,000	see remarks below.
Mar 13, 2024	kaufman jonathan h	acquired	99,999	0.6901	144,906	see remarks below.
Mar 13, 2024	chancellor michael b	acquired	99,999	0.6901	144,906	chief medical officer
Dec 22, 2022	chancellor michael b	acquired	131,962	5.75	22,950	chief medical officer

Which funds bought or sold LIPO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	new	-	15,120	15,120	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-17.57	-7,224	8,958	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	11.4	-1,777	5,280	-%
May 15, 2024	SABBY MANAGEMENT, LLC	reduced	-7.39	-104,045,000	171,181,000	0.10%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-14,100	28,831	-%
May 13, 2024	HRT FINANCIAL LP	new	-	7,000	7,000	-%
May 13, 2024	UBS Group AG	sold off	-100	-776	-	-%
May 13, 2024	FMR LLC	new	-	45.00	45.00	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	-11,564	23,646	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	3.45	-9.00	21.00	-%

Are Funds Buying or Selling LIPO?

Are funds buying LIPO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIPO

No. of Funds

Unveiling Lipella Pharmaceuticals Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 06, 2024	kaufman jonathan h	19.3%	1,608,349	SC 13D/A
Mar 19, 2024	kaufman jonathan h	21.0%	1,635,015	SC 13D/A
Mar 15, 2024	kaufman jonathan h	19.5%	1,500,015	SC 13D/A
Mar 15, 2024	chancellor michael b	20.0%	1,543,803	SC 13D/A
Mar 06, 2024	chancellor michael b	18.9%	1,398,897	SC 13D/A
Mar 06, 2024	kaufman jonathan h	18.3%	1,355,109	SC 13D/A
Feb 07, 2024	gruber michele	5.5%	365,000	SC 13G/A
Jan 25, 2024	huang leaf	9.6%	555,556	SC 13G/A
Jan 03, 2024	sabby management, llc	9.99%	579,814	SC 13G

Recent SEC filings of Lipella Pharmaceuticals Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 09, 2024	10-Q	Quarterly Report
May 06, 2024	SC 13D/A	13D - Major Acquisition
Apr 19, 2024	8-K	Current Report
Apr 12, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Lipella Pharmaceuticals Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Lipella Pharmaceuticals Inc. News

Latest updates

Lipella Pharmaceuticals Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	20.7%	145,880	120,842	104,051	106,676	118,048	151,007	-	-	33,149	-
Operating Expenses	60.3%	1,363,526	850,436	1,460,778	1,681,876	1,202,480	510,269	712,642	781,147	769,812	-
S&GA Expenses	-100.0%	-	396,236	627,518	624,231	508,750	32,167	61,688	38,487	93,850	-
R&D Expenses	85.5%	842,600	454,201	833,260	1,057,645	693,730	478,102	650,954	742,660	675,962	-
EBITDA Margin	3.2%	-9.92	-10.25	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	5,454	5,394	4,705	1,653	1,636	1,618	-
Earnings Before Taxes	-73.0%	-1,191,809	-688,884	-1,323,570	-1,538,686	-1,067,825	-363,924	-713,794	-782,024	-737,950	-
EBT Margin	3.3%	-9.93	-10.27	-8.95	-9.81	-10.88	-14.11	-9.19	-8.41	-7.76	-7.19
Net Income	-73.0%	-1,191,809	-688,884	-1,323,570	-1,538,686	-1,067,825	-363,924	-713,794	-782,024	-737,950	-
Net Income Margin	3.3%	-9.93	-10.27	-8.95	-9.81	-10.88	-14.11	-9.19	-8.41	-7.76	-7.19
Free Cashflow	100.0%	-	-727,710	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet							(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4
Assets	-12.3%	3,137	3,577	2,841	3,490	4,615	5,950	2,013
Current Assets	-12.2%	3,011	3,429	2,671	3,367	4,478	5,799	1,808
Cash Equivalents	-36.1%	2,105	3,294	2,410	3,114	4,019	5,122	1,414
Net PPE	-5.7%	12.00	13.00	13.00	-	-	-	-
Liabilities	33.1%	576	433	619	364	798	1,275	589
Current Liabilities	43.2%	552	385	549	299	717	1,178	341
Shareholder's Equity	-18.5%	2,561	3,144	2,222	3,125	3,816	4,676	1,424
Retained Earnings	-11.5%	-11,515	-10,323	-9,634	-8,311	-6,772	-5,704	-3,107
Additional Paid-In Capital	4.5%	14,076	13,468	11,856	11,436	10,589	10,380	4,530
Accumulated Depreciation	0.6%	128	128	127	-	-	126	-
Shares Outstanding	16.3%	7,040	6,054	5,804	5,744	5,744	5,744	3,867
Float	-	-	-	-	9,608	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)										(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-90.8%	-1,388	-727	-689	-655	-1,077	-231	-320	-579	-699	-
Cashflow From Investing	-	-	-	-	-	-	-	-	601	-300	-
Cashflow From Financing	-87.6%	200	1,612	-	-250	-25.00	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LIPO Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 145,880	$ 118,048
Cost and expenses
Research and development	842,600	693,730
General and administrative	520,926	508,750
Total costs and expenses	1,363,526	1,202,480
Loss from operations	(1,217,646)	(1,084,432)
Other income (expense)
Interest income, net	25,837	22,001
Interest expense related party		(5,394)
Total other income (expense)	25,837	16,607
Loss before income taxes	(1,191,809)	(1,067,825)
Provision for income taxes
Net Loss	$ (1,191,809)	$ (1,067,825)
Loss per common share
Basic	$ (0.16)	$ (0.19)
Dilutive	$ (0.16)	$ (0.19)
Weighted-average of common shares outstanding:
Basic	7,292,396	5,743,945
Dilutive	7,292,396	5,743,945
Grantrevenues [Member]
Total revenues	$ 145,880	$ 118,048

LIPO Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 2,105,299	$ 3,293,738
Grants receivable	68,934	32,286
Prepaid expenses	836,857	103,256
Total Current Assets	3,011,090	3,429,280
Property and Equipment
Furniture, fixtures and equipment	140,294	140,294
Furniture, fixtures and equipment (Accumulated Depreciation)	(128,265)	(127,544)
Furniture and fixtures, net	12,029	12,750
Other Assets
Operating lease right of use asset	114,038	135,144
Total Assets	3,137,157	3,577,174
Current liabilities
Accounts payable	293,835	138,016
Accrued expenses	84,929	77,280
Operating lease liability	91,705	89,223
Payroll liability	81,412	80,836
Total Current Liabilities	551,881	385,355
Operating lease liability, net of current portion	23,997	47,371
Total Liabilities	575,878	432,726
Stockholders’ equity:
Convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized; -0- shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value; 200,000,000 shares authorized, 7,039,846 and 6,053,956 shares issued and outstanding at March 31, 2024 and at December 31, 2023, respectively	704	605
Additional paid-in capital	14,076,227	13,467,686
Accumulated deficit	(11,515,652)	(10,323,843)
Total stockholders’ equity	2,561,279	3,144,448
Total liabilities and stockholders’ equity	$ 3,137,157	$ 3,577,174

About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

CEO	Dr. Jonathan Kaufman M.B.A., Ph.D.
WEBSITE	lipella.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Lipella Pharmaceuticals Inc. Frequently Asked Questions

What is the ticker symbol for Lipella Pharmaceuticals Inc.? What does LIPO stand for in stocks?

LIPO is the stock ticker symbol of Lipella Pharmaceuticals Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lipella Pharmaceuticals Inc. (LIPO)?

As of Fri May 17 2024, market cap of Lipella Pharmaceuticals Inc. is 5.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIPO stock?

You can check LIPO's fair value in chart for subscribers.

What is the fair value of LIPO stock?

You can check LIPO's fair value in chart for subscribers. The fair value of Lipella Pharmaceuticals Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lipella Pharmaceuticals Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIPO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lipella Pharmaceuticals Inc. a good stock to buy?

The fair value guage provides a quick view whether LIPO is over valued or under valued. Whether Lipella Pharmaceuticals Inc. is cheap or expensive depends on the assumptions which impact Lipella Pharmaceuticals Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIPO.

What is Lipella Pharmaceuticals Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LIPO's PE ratio (Price to Earnings) is -1.22 and Price to Sales (PS) ratio is 12.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIPO PE ratio will change depending on the future growth rate expectations of investors.